secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001806952-25-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma Q2 net loss narrows to $42.7M; raises $100M private placement; LYL314 shows 72% CR rate
--------------------------------------------------------------------------------

- Net loss of $42.7M in Q2 2025 vs $45.8M YoY; non-GAAP net loss $37.8M.
- Private placement up to $100M ($50M initial at $13.32/share); pro-forma cash $347M.
- LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL; manageable safety; PiNACLE pivotal trial initiated.
- R&D expenses $34.9M (-13% YoY); G&A expenses $9.8M (-20% YoY).
- Phase 3 trial for 2L LBCL expected by early 2026; LYL314 granted RMAT and Fast Track designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000180695225000007/0001806952-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000180695225000007/lyel-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001806952-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer